

Prevalence of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Patients with Pulmonary Tuberculosis in Zahedan, Southeastern Iran

Dear Editor,

Tuberculosis (TB) is responsible for a large portion of morbidity and mortality worldwide. According to WHO report, tuberculosis is responsible for at least 2 million deaths per year, so 90% of these occurring in developing countries.^{1,2} Recently, it has been shown that multidrug-resistance (MDR) and extensively drug-resistant tuberculosis (XDR-TB) are the most important factors cause death in patients with tuberculosis.^{3,4} Drug resistance of *M. tuberculosis* has been implicated in many etiologies such as inadequate and incomplete treatment, host genetic factors and, HIV infection.⁵⁻⁸ The long duration of treatment, large amount of anti-TB drugs and their gastrointestinal side effects, are the most important causes of noncompliance in patients with TB.⁴ MDR-TB (when resistance to isoniazid and rifampicin appears in combination), increases the numbers of individuals who need treatment with second-line drugs worldwide.^{9,10} After developments of MDR-TB, the development of resistance to second line drugs was another problem.⁵ XDR-TB is a form of TB caused by bacteria that are resistant to the most effective anti-TB drugs. XDR explained by resistance to both rifampin and isoniazid, as well as to fluoroquinolones plus an injectable agent and Pre-XDR TB isolates are multidrug resistant bacilli which are resistant to either a fluoroquinolone or an injectable agent, but not both.¹¹ Some believe that XDR-TB strains have emerged from the mismanagement of multidrug-resistant TB and once created, can spread from one person to another.^{7,12} TB and drug resistant tuberculosis is also a serious public health problem in Iran as other developing countries. According to the World Health Organization, the estimated incidence rate of TB in Iran is 28 cases per 100,000 population.^{2,6} In a report from Southest of Iran, among patients with PTB in Zahedan, where the incidence rate of TB is higher than other regions of Iran, 16% of patients with PTB had MDR TB.⁹ XDR-TB is higher in patients with MDR-TB and mortality in XDR-TB is higher than MDR-TB.⁷ Recent report in Iran showed that 5.3% of patients with PTB had MDR-TB and of these patients, 10.9% had XDR-TB.⁷ Since, there were few reports

about MDR-TB and no any data about the prevalence of XDR-TB in Zahedan, we decided to evaluate them.

From January 2007 to January 2008, we evaluated all patients with a positive sputum culture who referred to our hospital (Research Center for Infectious Diseases and Tropical Medicine). First, all patients who had clinical signs and symptoms suggestive of PTB were enrolled. These patients were asked to participate in our study. If they accepted, they underwent testing including Ziehl-Neelsen staining and culture. Patients who subsequently were culture-negative for *Mycobacterium tuberculosis* were withdrawn from the study. Then, we analyzed all culture-positive cases of *Mycobacterium tuberculosis* infection referred to our TB center. Primary isolation and culture of *Mycobacterium* isolates, after NaOH-N-acetylcysteine was done in conformity with standard solid-culture procedures.¹³ All isolates were identified as *M. tuberculosis* complex with use of standard biochemical tests, including niacin activity, production of catalase and nitrate reduction, as well as the registration of pigment production and growth rate. Drug susceptibility testing against isoniazid and rifampicin was done by the proportional method on Loewenstein-Jensen media at a concentration of 0.1 and 0.001 mg/mL.¹⁴ Drug-susceptibility testing against second-line drugs (amikacin, kanamycin, capreomycin, ciprofloxacin, levofloxacin) was carried out using 2 critical proportions of 0.1 and 0.001. All of these drugs were purchased from glaxo Chemical. Clinical and Epidemiological Information collected from patients with confirmed cases of TB by trained technicians using standard questionnaires. Information obtained on sex, age, previous history of TB, present address, and associated medical data such as chest radiograph findings and presence of HIV infection. Patients also required to have drug-susceptibility test results that showed resistance to isoniazid and rifampin (as MDR-TB), as well as chest radiograph findings and clinical signs and symptoms that were compatible with PTB. Statistical analysis was performed using SPSS, version 11. Data were analyzed by Chi-Square test and $p < 0.05$ was considered significant.

This prospective study was conducted using a total of eighty eight patients (40% male, 60% female) with positive sputum culture for *M. tuberculosis* complex. The patients aged between 15 and 94 years. 90% of patients were Iranian and 10% were Afghan. 12.2% of our patients had MDR-TB (3 females; 6 males) and one subject with pre-XDR-TB (resistant to capreomycin) identified. No case had XDR-TB. 8% of culture positive patients had a negative sputum smear and two cases had HIV infection. Ten patients (8.8%) had a past history of treatment for tuberculosis. Among previously treated patients, 44% had MDR-TB. Among patients who had received a new diagnosis, 10% had MDR-TB.

Our results showed that 12.2% of our patients had MDR-TB. One patient with pre-XDR-TB (capreomycin resistance) identified; and there was no case of XDR-TB. Tuberculosis is a serious public health problem in Iran as other developing countries and MDR-TB is a very important and serious health problem among patients with tuberculosis.^{9,10} Extensively drug-resistant tuberculosis has also recently emerged as a global health problem, threatening the success of TB control programs in the world.^{7,15,16} There are many reports which show MDR and XDR-TB are increasing worldwide. Recent studies in Iran also showed that both MDR and XDR-TB were increasing especially among patients treated within inappropriate regimens or when patients became selectively non-compliant by not taking all of the 3 or 4 drugs.^{4,9,10} Masjedi *et al.* reported results of susceptibility to first-line drugs performed for 1284 *Mycobacterium tuberculosis* isolates who were referred to the National Research Institute of Tuberculosis and Lung Diseases (Tehran, Iran) for treatment and diagnosis from 2003 to 2005. Subsequently, the strains which were identified as multidrug-resistant *M. tuberculosis* (113 isolates) were subjected to susceptibility testing for second line drugs. A total of 12 (10.9%) of 113 multidrug-resistant *M. tuberculosis* strains were XDR *M. tuberculosis*.⁷ Shamimi and his colleagues reported 2% of 548 patients had MDR-TB.¹⁷ Another

study in Southeast Iran by Naserpour and colleagues showed that 16% of patients with PTB had MDR-TB.⁸ There was no any XDR-TB among patients in these two recent studies. A global survey in reference laboratories for TB isolates during 2000–2004 identified XDR-TB in 17 countries and estimated that 10% of the sampled multidrug-resistant (MDR) TB strains were XDR.¹⁸ A study in California during 1993–2006, identified 18 XDR-TB cases who had poor outcomes. None of the patients in California with XDR-TB had AIDS.¹⁹

In conclusion, 12.2% of patients had MDR-TB. There was no patient with XDR-TB in our study. We recommend drug-susceptibility testing on the first-line drugs in any patient with tuberculosis in the beginning of treatment.

Acknowledgment

This project was financially supported by Research Department of Zahedan University of Medical Sciences. We would like to thank Mis Saiede Mirfakhraie and all staff in Zahedan research center of infectious diseases and tropical medicine.

Keywords: Pulmonary; Tuberculosis; Multidrug-resistant; Extensively drug-resistant

Conflict of interest: None declared.

M Metanat, B Sharifi-Mood*, Sh Shahreki, S-H Dawoudi

Research Center for Infectious Diseases and Tropical Medicine, Zahedan University of Medical sciences, Zahedan, Iran

***Correspondence:** Batool Sharifi-Mood, MD, Research Center for Infectious Diseases and Tropical Medicine, Boo-Ali Hospital, Zahedan University of Medical Sciences, Zahedan, Iran. Tel: +98-541-3236969, Fax: +98-541-3212975, e-mail: batoolsharifi@yahoo.com
Received: May 15, 2011 Accepted: August 12, 2011

References

- 1 Pablos-Méndez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, Cohn DL, Lambregts-van Weezenbeek CS, Kim SJ, Chaulet P, Nunn P. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. *N Engl J Med* 1998;**338**:1641-49. [9614254]
- 2 Sharifi-Mood B, Alavi-naini R, Metanat M. Relapse rate and Failure rate in hospitalized smear positive Pulmonary TB in: 2nd National congress of Epidemiology, Zahedan, Iran, 2004.
- 3 Petrini B, Hoffner S. Drug-resistant and multidrug-resistant tubercle bacilli. *Int J Antimicrob Agents* 1999;

- 13:93-7. [10595567] [[http://dx.doi.org/10.1016/S0924-8579\(99\)00111-9](http://dx.doi.org/10.1016/S0924-8579(99)00111-9)]
- 4 Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of *Mycobacterium tuberculosis* in KwaZulu-Natal, South Africa. *Clin Infect Dis* 2007;**45**:1409-14. [17990220] [<http://dx.doi.org/10.1086/522987>]
 - 5 Tounghousova OS, Mariandyshev AO, Bjune G, Caugant DA, Sandven P. Resistance of multidrug-resistant strains of *Mycobacterium tuberculosis* from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs. *Eur J Clin Microbiol Infect Dis* 2005;**24**:202-6. [15742171] [<http://dx.doi.org/10.1007/s10096-005-1284-z>]
 - 6 World Health Organization (WHO). Stop TB Partnership annual report 2004. WHO/HTM/STB/2005.33. Geneva, Switzerland: WHO, 2005.
 - 7 Masjedi MR, Farnia P, Sorooch S, Pooramiri MV, Mansoori SD, Zarifi AZ, Akbarvelayati A, Hoffner S. Extensively drug-resistant tuberculosis: 2 year of surveillance in Iran. *Clin Infect Dis* 2006;**43**:841-7. [16941364] [<http://dx.doi.org/10.1086/507542>]
 - 8 Davarpanah MA, Rafiee GH, Mehrabani D. The prevalence of *M. tuberculosis* infection and disease in HIV positive individuals in Shiraz, Southern Iran. *Iran Red Crescent Med J* 2009;**11**:199-202.
 - 9 Naserpour T, Naderi M, Mohagheghfard Fard AH, Sharifi-Moud B, Rezai E. Drug Resistance of *Mycobacterium Tuberculosis* Strains Isolated from Patients with Pulmonary Tuberculosis in South Eastern of Iran. *Journal of Medical Sciences* 2006;**6**:321-4.
 - 10 Mirsaedi SM, Tabarsi P, Khoshnood K, Pooramiri MV, Rowhani-Rahbar A, Mansoori SD, Masjedi H, Zahirifard S, Mohammadi F, Farnia P, Masjedi MR, Velayati AA. Treatment of multidrug-resistant tuberculosis (MDR-TB) in Iran (preliminary report). *Int J Infect Dis* 2005;**9**:317-22. [16183321] [<http://dx.doi.org/10.1016/j.ijid.2004.09.012>]
 - 11 Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, Laserson KF, Wells CD. Clinical outcome of individualized treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. *Lancet* 2005;**365**:318-26. [15664227]
 - 12 Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martin-Casabona N, Drobniewski F, Gilpin C, Havelková M, Lepe R, Lumb R, Metchock B, Portaels F, Rodrigues MF, Rüsch-Gerdes S, Van Deun A, Vincent V, Laserson K, Wells C, Cegielski JP. Worldwide emergence of extensively drug-resistant tuberculosis. *Emerg Infect Dis* 2007;**13**:380-7. [17552090] [<http://dx.doi.org/10.3201/eid1303.061400>]
 - 13 Kent PT, Kubica GP. Public health mycobacteriology: a guide for level III laboratory. Atlanta, GA: Public Health Services, US Department of Health and Human Services, Centers for Diseases Control, 1985.
 - 14 Kleeberg HH, Koornhof HJ, Palmert H. Susceptibility testing. In: Nel EE, Kleeberg HH, Gatner EMS, eds. Laboratory manual of tuberculosis methods. 2nd ed. Pretoria, South Africa: South African Medical Research Council, 1980.
 - 15 Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. *Lancet* 2006;**368**:1575-80. [17084757] [[http://dx.doi.org/10.1016/S0140-6736\(06\)69573-1](http://dx.doi.org/10.1016/S0140-6736(06)69573-1)]
 - 16 Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. *Wkly Epidemiol Rec* 2006;**81**:430-2. [17096498]
 - 17 Shamaei M, Marjani M, Chitsaz E, Kazempour M, Esmaili M, Farnia P, Tabarsi P, Amiri MV, Mirsaedi M, Mansouri D, Masjedi MR, Velayati AA. First line anti-tuberculosis drug resistant pattern and trends at the national TB referral center in Iran-eight years of surveillance. *Int J Infect Dis* 2009;**13**:e236-40. [19285897] [<http://dx.doi.org/10.1016/j.ijid.2008.11.027>]
 - 18 Centers for Disease Control and Prevention (CDC). Emergence of *Mycobacterium tuberculosis* with extensive resistance to second-line drugs-worldwide, 2000-2004. *MMWR Morb Mortal Wkly Rep* 2006;**55**:301-5. [16557213]
 - 19 Banerjee R, Allen J, Westenhouse J, Oh P, Elms W, Desmond E, Nitta A, Royce S, Flood J. Extensively drug-resistant tuberculosis in California, 1993-2006. *Clin Infect Dis* 2008;**47**:450-7. [18616396] [<http://dx.doi.org/10.1086/590009>]